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Abstract
Photodynamic therapy (PDT) employs light activation of tissue‐localized photosensitizer 
in an oxygen‐dependent process which initiates oxidative stress, inflammation, and cell 
death. Photodynamic therapy (PDT) involves the activation of a previously administered 
photosensitizing agent by visible light to induce tumor necrosis. Photosensitizers are 
topically applied in the treatment of skin tumors to avoid systemic side effects. The main 
dermatology indications for topical PDT are superficial nonmelanoma skin cancer and 
dysplasia, notably superficial basal carcinoma (BCC), Bowen's disease (BD), and actinic 
keratosis (AK). In this chapter, we evaluated the feasibility and efficacy of aminolevulinic 
acid (ALA) as a photosensitizer (ALA‐PDT) in combination with CO
2
 laser in the treat‐
ment of dermatological disease from basics to clinic research.
Keywords: photodynamic therapy, photosensitizer, Bowen's disease, actinic keratosis, 
aminolevulinic acid
1. Photodynamic therapy for actinic keratoses
Skin aging is often divided into natural aging and photoaging. Photoaging is caused by exces‐
sive exposure to the ultraviolet (UV) irradiation. The skin becomes thick and rough, with 
coarse wrinkles, mottled pigmentation, and precancerous lesions, including actinic keratoses 
(AK). Actinic keratosis (AK) is a growth of dysplastic cells within the epidermis that presents 
clinically with a scaly localized macule or papule on chronically sun‐exposed skin [1]. Over 
the last few years, the relationship between AK and SCC has been a topic for much debate in 
the literature, as AK is believed not to be a separate entity but an SCC in situ.
Some researchers also consider actinic keratoses equivalent to squamous cell carcinoma 
(SCC). Yet, SCC is capable of metastasis [2, 3]. So it can be life threatening. AK is a precancer‐
ous lesion, therefore should be treated early. There are a lot of methods for AK, while not all 
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treatments are appropriate for all patients or lesions, especially cosmetic outcome may be 
generally less than optimal [4, 5]. The ideal treatment for AKs should be effective, well toler‐
ated, and have an excellent cosmetic outcome, particularly in cosmetic‐sensitive areas such 
as the face.
Photodynamic therapy (PDT) has been under development for the treatment of various 
tumors by the end of the 1970s. Topical ALA‐PDT was originally used for superficial non‐
melanoma skin cancers and their precursors. However, other benign diseases, such as acne 
vulgaris, sebaceous gland hyperplasia, and hidradenitis suppurativa, have been shown to 
improve with this treatment. Photodynamic therapy (PDT) is an alternative, minimally inva‐
sive treatment. Oxygen, photosensitizer, and light are the three principal elements of PDT. 
When illuminated by a light source with an appropriate wavelength, the photosensitizer is 
activated and will react with oxygen to produce singlet oxygen and reactive oxygen spe‐
cies (ROS) to cause the selective destruction of target tissues [6]. As a metabolic precursor of 
endogenous porphyrins in heme biosynthesis, the absorption of 5‐ALA induces the produc‐
tion and accumulation of protoporphyrin IX (Pp IX), a fluorescent substance that is as effec‐
tive as a light sensitive agent (408, 506, 532, 580, and 635 nm).
An ideal treatment for AK would only affect lesional skin, leaving normal surrounding skin 
unharmed. In the 1990s, Kennedy et al. using topic 5‐aminolaevulinic acid (5‐ALA) that has 
restricted the phototoxicity at the application site. Since AK lesions are capable of selectively 
accumulating PPIX, they are excellent targets for PDT.
Forty‐two patients with a total of 56 AK lesions on the face were enrolled in our study. The 
5‐ALA (Zhangjiang, China) was prepared at a concentration of 20% in physiological saline. 
A thick layer of the formulation was applied to cover the AK lesions for 5 h. Then the lesions 
were illuminated by laser (λ = 630 nm, light dose 100 mW/cm2) for 30 minutes All patients 
were reviewed in at least 2‐week intervals. The response to the PDT was evaluated 1 month 
after the therapy, and treatment is repeated if necessary [7].
Initially, AKs lesions were detected among the patients (Figure 1). The treated skin lesions 
were evaluated macroscopically at several time points following the treatment. Immediately 
after ALA‐PDT, it showed limited edema and erythema in the treated area. Conversely, the 
lesions were covered with necrotic tissue after 1 day. A red granulation tissue developed after 
4–7 days and gradually atrophic flatten (Figure 2). Afterwards, a pink‐red contracted atro‐
phic scar could be observed that progressively healed after 3 weeks. All the 56 lesions from 
42 patients showed a complete response by histologic examination (remission rate, 85.71%) 
1 month after PDT treatment. The epidermis of the photodamaged skin became thinner and 
more even. Clinically, there was no significant scarring or pigmentary changes after treatment 
(Figure 3).
There were six patients with persistent lesions, the six patients with eight lesions received 
one or two additional PDT treatments; the AKs in the follow‐up biopsy resolved, and the 
lesions were all cleared in the end.
Before treatment, histopathological analysis of the lesions showed the presence of atypi‐
cal keratinocytes characteristic for AK (Figure 4). After treatment, the epidermis of the 
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 photodamaged skin became thinner and more even, and the skin structure in responsive 
lesions had returned to normal and the atypical cells of AK were replaced by normal kerati‐
nocytes (Figure 5). The epidermis was fully regenerated by day 30 following PDT.
The facial lesions’ mean epidermal thickness significantly decreased from 155.22 ± 70.45 to 
74.35 ± 18.65 μm after treatment (P < 0.05) (Figure 6). We can observe a large number of 
 infiltrating cells in the dermis before the treatment, and those were significantly reduced after 
treatment. In 5 h of 5‐ALA occlusive treatment, there were no reports of irritation, local or 




Figure 2. 1 week after PDT.
Photomedicine - Advances in Clinical Practice40




Figure 4. Before PDT.
Figure 5. After PDT.
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systemic light sensitization reaction. During the exposure to the light source all patients com‐
plained about a burning sensation, ranging from light to intense. During the treatment, vari‐
able degrees of erythema, blistering and edema occurred, all of these events were of short 
duration and completely reversible. During the treatment, it was possible to see progres‐
sive and evident edema and erythema on the application site. Despite the pain, none of the 
patients asked or interrupted the light exposition treatment.
The cosmetic outcome in all cured AKs was excellent, except for one patient; after additional 
sun exposure, postinflammatory hyperpigmentation developed. The method of topical appli‐
cation of ALA is a minimally invasive treatment. Photosensitizer's metabolic cycle is very 
quick, the period of photosenisitization is short, and can give good cosmetic effect.
The investigations of the action of light on living organisms began in the nineteenth century. 
Since Dougherty [8] in the 1970s began clinical trials for photodynamic destruction of cutane‐
ous and subcutaneous malignancies, PDT has been used to treat esophageal [9], laryngeal, 
endobronchial, gastrointestinal, genitourinary, nervous, head and neck [10], oral leucoplakia, 
and skin malignancies [11].
Photodynamic therapy (PDT) is an oxygen‐dependent process involving the use of a pho‐
tosensitizing drug which accumulates in diseased tissue. The main topical agents used in 
dermatology are 20% 5‐aminolaevulinic acid (ALA). It produced porphyrins via the heme bio‐
synthetic pathway. It is an endogenous chemical, which participates in heme biosynthesis in 
the body. As a precursor of the hemoglobin content, its production has strong photosensitive 
function after the activation of ALA anhydrase and a series of enzymes. Porphyrin IX (pro‐
toporphyrin IX, Pp IX) is the last step of heme biosynthesis intermediate [12]. Under normal 
circumstances, heme biosynthesis pathway by regulating the body negative feedback mecha‐
nism, the synthesis of ALA is regulated by the hemoglobin content in the cell, so there will 
not be too much ALA accumulation in the body. When given overdoses of exogenous ALA, it 




can increase the intracellular concentration of Pp IX to therapeutically useful  concentrations. 
Photoactivation by visible light results in cell damage of targeted abnormal cells while pre‐
serving normal structures. This effect of PDT is connected with direct photochemical reactions 
mediated by singlet oxygen and other reactive species. The cooperation of photosensitizing 
substances with light leads to the release of cytotoxic substances. It has been described that 
tumor destruction of PDT is connected with indirect effects of PDT: blood vessel occlusion 
within vascularized tumors. These effects demonstrated [9] that PDT induces apoptosis and 
vascular endothelial damage [13, 14]. It has also been mediated by the release of prostaglandin 
E2 (PGE2) and cytokines (IL‐2, IL‐ 1, TNF).
In this study, we observed pre‐ and post‐ ALA‐PDT specimens for AK and determined 
whether ALA‐PDT induced histologic changes reversing the destructive connective tissue 
events. Normally, we selected 1 month after the PDT as the point time to evaluate the histologic 
changes for lots of results showing this time point of the assessment might be an important 
consideration. The fact that 1–20% of AKs progress to squamous cell carcinoma and approxi‐
mately 60% of all squamous cell carcinomas develop from AKs underscores the importance of 
early treatment of AKs [3]. Our findings showed approximately 85% of AKs are already cured 
after a single PDT exposure. As a result, the majority of patients need only one treatment, and 
we only performed one PDT session followed by clinical examinations at 1 and 3 months after 
PDT. Only those lesions that showed an incomplete response need further treatment.
• The results of this study provide histologic evidence supporting the beneficial effects of 
ALA‐PDT for photodamaged skin. PDT appears to be a more feasible alternative to con‐
ventional therapy of skin malignancies. Our results showed that the thickness of epidermis 
decreased significantly after ALA‐PDT. We could see hyperkeratosis, stratum spinosum 
hypertrophy before the treatment. And the acanthocyte arranged in disorder. There are 
atypical keratinocytes in the central of the epidermis. We evaluated the histologic changes 
1 month after the PDT, suggesting that the point in time of the assessment might be an 
important consideration. The epidermis was fully regenerated by day 30 following PDT. 
After treatment, the epidermis of the photodamaged skin became thinner and more even, 
and the skin structure in responsive lesions had returned to normal and the atypical cells of 
epidermis were replaced by normal keratinocyte [7]. Although the light source itself might 
affect the histologic changes in AKs, we still consider that ALA‐PDT is the most important 
reason leading to the histologic changes in the present study where the light energy is very 
low.
Topically applied photosensitizers are preferred for dermatological PDT because of the 
reduced risk for prolonged skin photosensitivity. As we all know, topical application of ALA 
is a minimally invasive treatment. It has a short photosenisitization period, can treat multiple 
lesions at the same time, and can give good cosmetic effect. Studies have shown that the 
depth of penetration for most tissues using 630 nm light is about 1 cm [15, 16]. This percu‐
taneous penetration is the most important factor influencing response rates for topical ALA 
PDT. Photodynamic therapy is associated with epidermal necrosis and dermal inflammation, 
which in turn gives a series of side effects in dermatology, including pain, ecchymosis, ulcer‐
ation, and blistering [17].
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Selective photodynamic destruction of treated premalignant and malignant areas without 
injury of normal tissue, ability to repeat PDT without loss of normal tissue proves PDT to be 
a more acceptable option than surgical resection. At the same time, laser‐induced PDT almost 
left no obvious scar in our study. Patients treated with PDT may also benefit from minimal 
invasiveness, low recurrence, as well as excellent cosmetic effects in premalignant and malig‐
nant lesions of the skin.
The present study is limited by the follow‐up time. In our study at 1 and 3 months after PDT, 
previous reports are in good agreement with the overall CR rates of 85.71 and 100% that were 
found, respectively. However, there are still existed residual malignant cells in the epidermis 
but not apparent by visual inspection. It will lead to clinical recurrence of the AKs at a later 
examination if the malignant cells continue to proliferate. That is the important reason why 
we need to observe the clearance rate after PDT for a long follow‐up time.
In conclusion, the results of this study provide histologic evidence supporting the beneficial 
effects of PDT for AK. PDT using topical ALA was a safe and effective treatment for actinic 
keratoses with an excellent cosmetic outcome. It is a promising treatment that could benefit 
from further study. Topical PDT for AKs is now a well‐established treatment modality that 
showed easy handling of 5‐ALA administration with excellent efficacy and safety results.
2. Photodynamic therapy for the treatment of Bowen's disease
Bowen's disease (BD), or squamous cell carcinoma in situ, usually presents as a well‐defined 
erythematous plaque on photoexposed sites [18]. Although any body part can be involved, 
BD lesions are common on the head and neck and lower limbs. The diagnosis is often delayed 
because of the symptoms are often untypical. The early skin changes may often appear to be 
eczema, tinea corporis, and psoriasis. Therefore, pathological diagnosis might be necessary 
when clinical differentiation between these diseases is difficult [3].
BD is a more aggressive form of intraepidermal (in situ) squamous cell carcinoma. Risk fac‐
tors for BD include fair skin, protracted sunlight damage, radiation exposure, immune com‐
promise and human papillomavirus infection [19]. Most BD lesions are found in the elderly 
patients commonly at high risk for surgery.
Several equally efficacious treatment options are available for the treatment of BD including 
conventional surgery, Mohs’ surgery, cryosurgery, and CO
2
 laser. However, it is not indicated 
for patients with numerous or large lesions such as those located in face. Alternative treat‐
ments are needed to treat superficial malignancies on nose, ear, and other sites. CO
2
 laser 
vaporizes lesional tissues by thermal effects and causes minimal injuries, but it often fails to 
entirely remove lesions, especially those invisible or infiltrating into adjacent tissues, result‐
ing in disease persistence and recurrence.
Topical 5‐aminolevulinic acid‐mediated photodynamic therapy (ALA‐PDT) is a minimally 
invasive procedure, represents a relatively new treatment modality, and, with some unique 




causes less damage to normal tissues than surgical treatment, radiation therapy, or chemo‐
therapy. In addition, since PDT does not produce cumulative effect and systemic phototoxic‐
ity, it allows repetitive treatments for new, partially responding or recurrent lesions. In this 
study, ALA‐PDT treatment was performed following local pretreatment with CO
2
 laser. By 
the pretreatment, we could enhance photosensitizer absorption, reduce the thickness of the 
BD lesion, and even increase the penetration depth of the irradiation, to achieve a multiplier 
effect [20].
Twenty‐two lesions from 18 patients were randomized into two groups [21]; 11 lesions were 
treated with CO
2
 laser alone, serving as control group. The remaining 11 lesions were treated 
with topical ALA‐PDT (180 J/cm2 at 100 mW/cm2) + CO
2
 laser for 1–3 sessions.
Biopsies were taken from BD lesions prior to treatment. BD is histopathologically character‐
ized by the presence of atypical keratinocytes (Figure 7). Skin biopsies from the erythematous 
plaque exhibited proliferation of atypical squamous cells across the entire thickness of the 
epidermis and the BD diagnosis was based on the finding. The initial evaluation was under‐
taken 1 month after treatment and biopsies were harvested for histological evaluation. The 
epidermis fully regenerated in the point of 30 days after ALA‐PDT + CO
2
 laser treatment. The 
epidermis of the BD lesion became thinner and more even following the treatment. Moreover, 
the atypical BD cells were replaced by normal keratinocytes and the skin structure in respon‐
sive lesions returned to normal (Figure 8). All patients were reviewed at ≤1‐week intervals. 
Patients who did not respond to the three sessions of treatment were referred to surgical 
treatment [21].
Figure 7. Before PDT (×20).
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In the CO
2
 laser group, eight patients who underwent 1–3 sessions of laser treatment alone 
showed response to the therapy. Seven lesions (63.63%) achieved complete recovery, three 
(27.27%) showed partial response but another five lesions (45.45%) relapsed within 6 months 




In the ALA‐PDT + CO
2
 laser group, complete response was achieved in 72.73% of the lesions 
after 1–3 treatment sessions. Three lesions (27.27%) showed partial response during the treat‐
ment. ALA‐PDT + CO
2
 laser was repeated in the cases of partial response after a single ses‐
sion. Out of eight lesions that initially responded completely, 1 month later one relapsed. The 
recurrence rate was 9.1% (1/11) and the overall clearance was 90.9% (10/11). Eight out of 10 
(80%) patients were satisfied with their therapeutic outcome after ALA‐PDT + CO
2
 laser treat‐
ment, which is much higher than control group [21].
BD lesions are commonly seen on the head, neck, and lower limbs, although any site can be 
involved. The combination treatment of ALA‐PDT and CO
2
 laser could achieve a much bet‐
ter cosmetic outcome. Compared with CO
2
 laser alone, histopathological examination of the 
BD lesions confirmed that the response to the combination therapy was more uniform after 
ALA‐PDT + CO
2
 laser. PDT appears to be a more feasible alternative to conventional therapy 
for skin malignancies. BD lesions predominantly consisted of atypical keratinocytes before 
the treatment. We can see the large number of atypical cells in the epidermis and superficial 
layers of the dermis, a few lymphocytes and dilated capillaries. Following ALA‐PDT + CO
2
 
laser treatment, the epidermis was found to have fully regenerated 30 days. Furthermore, 
the stratum spinosum become thinner after treatment, the atypical BD cells were replaced by 




normal keratinocytes and the photodamaged skin architecture in responsive lesions returned 
to normal.
Our study also showed that local ALA‐PDT after CO
2
 laser was highly effective for BD lesions 
and could be used as an ideal alternative for large and multiple BD lesions, or for other 
modalities of treatment (surgical or nonsurgical) are inappropriate or have failed. There was 
no difference in the complete remission rate between the two groups (P > 0.05). However, 
recurrence of BD at the treated site is common. The recurrence rate was substantially higher 
in the control group than in the ALA‐PDT + CO
2
 laser group (P < 0.05). While the overall clear‐
ance was higher in the ALA‐PDT + CO
2
 laser group than in the control group (P < 0.05). A 
complete response was seen in 72.73% of lesions after 1–3 treatment sessions. Only one lesion 
developed recurrence 6 month after ALA‐PDT + CO
2
 laser treatment. The post‐treatment 
recurrence rate was 45.45% (5/11) in CO
2
 laser alone group, and five lesions relapsed within 
6 months during follow‐up. In general, we consider incomplete clearance after four or more 
times of PDT treatments to be a PDT failure. In terms of our experience, the vast majority of 
patients were cured within two or three treatment cycles. We would advise patients select 
alternative treatments in this failure situation. Recurrent disease can be retreated by PDT. 
This is another advantage of PDT and particularly applied for large or multiple areas and 
field change. Figure 9 showed a 55‐year‐old male hepatitis B patient who has 6‐month history 
of genital BD lesions. He underwent three sessions of ALA‐PDT + CO
2
 laser treatments, and 
he completely recovered from BD. He revealed no recurrence during the 6‐month follow‐up 
after treatment (Figure 10).
In most cases, PDT plus superficial laser vaporization was usually given as a single outpatient 
treatment that gave good therapeutic results. Most treatments are not suitable for BD lesions 
involving large and multiple lesions, but we used PDT for BD lesions in some sites such as 
peri‐genital areas, and succeed in the end. The efficacy of local ALA‐PDT after CO
2
 laser for 
Bowen's disease lesions reaches almost 80–90%. Compared with the efficacy of PDT with 
laser in the treatment of Bowen's disease demonstrated that PDT was better than laser alone 
[14, 22]. Compared with other treatments, PDT causes the low incidences of ulceration and 
absence of infections.
BD may be a prototype of a non‐melanoma skin cancer, and clinically PDT should be seen as 
a first‐line therapy, especially for elderly patients who find the need for hospital attendance 
limiting [23]. Many BD lesions require immediate surgical intervention in order to avoid the 
risk of malignant change. With local ALA and light illumination combined with CO
2
 laser, 
good results can be accomplished usually with a single outpatient treatment session without 
causing serious side effects except a few patients had transient pain, erythema, and scabby.
The most common side effect experienced with PDT is pain, with up to 20% of patients 
describing pain as being “severe”. This can sometimes persist for a few hours after treatment, 
and it tends to be severest during the early period of irradiation. Postinflammatory hyper or 
hypopigmentation can also occur. Persistent erythema is often seen at 3 months but does not 
necessarily indicate residual disease [24, 25].
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This study explored the feasibility of using topical ALA‐PDT combined with CO
2
 laser for BD. 
Our preliminary results proved that the ALA‐PDT after CO
2
 laser is safe and effective and is 
associated with a low recurrence rate. The main limiting factors for PDT at the moment are 
pain and the inconvenience of hospital attendance. However, this study provided histological 
evidence that supports the beneficial effects of ALA‐PDT + CO
2
 laser for the treatment of BD. 
PDT is quite promising and could be the potential alternative, especially for large and mul‐
tiple lesions; or for patients where other modalities of treatment (surgical or non‐surgical) are 
inappropriate or have failed.




3. Photodynamic therapy for the treatment of port wine stains
Port‐wine stain (PWS) is congenital vascular malformation characterized by ectatic capillaries in 
the papillary layer of the dermis. PWS occurs in an estimated 0.3% of births, affecting males and 
females and all racial groups equally. It may be located anywhere on the body, but more often 
on the face. PWS are permanent, do not disappear spontaneously. They usually appear at birth 
and tend to become darker and thicker with age [26, 27], deepening in color from faint pink to 
deep red or purple or developing nodularity. It is usually isolated but may be associated with 
other vascular malformations or occurs as a component of a variety of congenital syndromes.
Figure 10. After PDT.
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Because persistent PWS lesions can cause serious psychological problems, therapy for PWS 
is considered a medical necessity. Many therapeutic methods have been used to treat PWS, 
including surgical excision, cryosurgery, dermabrasion, tattooing, and cosmetic camouflage 
makeup [28]. These methods are no longer used because of ineffectiveness and scarring.
PDT is a relatively new therapeutic modality for skin disease. The vascular effects of PDT 
on tumors leads to endothelial injury, vasoconstriction, thrombus formation, and blood flow 
stasis. These results suggest that PDT is a potential treatment for certain vascular diseases, 
including PWS. The advantage of PDT is its dual selectivity: precise direction of laser light 
to the specific target area and selective uptake of photosensitizer to target tissues. PWS have 
a histologic characteristic of dilated capillary vessels, the target of PDT. In vivo 23–26 and 
in vitro 25 studies have shown that photosensitizer accumulation occurs rapidly in vascular 
endothelial cells after intravenous administration.
Recently, the General Hospital of the Peoples’ Liberation Army in China reported their decade‐
long experience of PWS with PDT. Gu et al. [29, 30] reported that among 1942 PWS lesions in 
1385 patients treated by either PSD‐007 or HMME from April 1991 to May 2003 showed that, 
after one PDT treatment session, total clearance was achieved in 128 lesions (6.6%), achieved 
excellent results, 746 (38.3%) good results, 923 (47.4%) fair results, 145 (7.4%) results, and seven 
(0.3%) with no visible change. Their data showed that PDT was an effective treatment in all 
patients with PWS, especially for dark‐skinned patients or patients with papules or nodules.
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